Best position ever ., page-37

Here's one many here might like.

According to a recently published research paper (https://link.springer.com/article/10.1007/s43441-021-00364-y) analysing orphan and non-orphan drug company investment returns over 2005-2020 the average valuation of orphan drug companies at different stages was (N = ~50 companies, USD converted to AUD):

Pre-clinical $100m
Phase 1 $800m
Phase 2 $1.4B
Phase 3 $3B
Approved $4.5B

Multi-indication companies were also worth ~2x singe-indication ones i.e. these averages included both multi and single indications. This means the average for multi-indications was therefore quite a bit higher than the above numbers.

So Neuren is still somewhere between pre-clinical and Phase 1...